Could a protein on blood vessel cells be key to treating a rare heart condition?
NCT ID NCT07697183
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study investigates whether a drug called XBD173, which targets a protein (TSPO) on blood vessel lining cells, can help understand how these cells contribute to pulmonary artery hypertension (PAH). PAH is a rare condition where narrowed lung blood vessels strain the heart. Six adults with PAH and an implanted heart monitor will take XBD173 for 6 weeks, with heart and lung scans before and after. The goal is to see if changes in blood markers relate to changes in blood vessel resistance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XBD173
- What this could lead to
- If successful, this could point toward a new treatment approach for pulmonary artery hypertension by targeting blood vessel lining cells.
- What could go wrong
- This is a very small early-phase study with only 6 participants, so results may not apply broadly. The drug may show no effect on blood vessel function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NIHR Imperial CRF
London, W12 0HS, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.